Literature DB >> 25023045

Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh.

Shahinul Alam1, Utpal Das Gupta, Mahbubul Alam, Jahangir Kabir, Ziaur Rahman Chowdhury, A K M Khorshed Alam.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is considered to be a disease of obese individuals, yet lean patients are increasingly susceptible to have NAFLD. The aim of this study was to evaluate the profile of nonobese patients by comparing with obese NAFLD patients.
METHODS: We have included 465 patients of NAFLD after exclusion of other diseases, and 220 with elevated alanine aminotransferase (ALT) were biopsied. Patients were biochemically and clinically evaluated: blood pressure, body mass index (BMI), and waist circumference (WC) were recorded for every patient. A BMI  ≥ 25 kg/m(2) was defined as obese, and those with a BMI of <25 kg/m(2) were labeled as nonobese. Histological activity was expressed with NAFLD activity score (NAS).
RESULTS: Of 465 cases, 119 (25.6 %) were nonobese. Diabetes was noted in 122 (26.2 %) and hypertension in 122 (26.2 %). Metabolic syndrome was present in 253 (59.7 %), low HDL cholesterol in 228 (64.8 %), hypertriglyceridemia in 297 (73.2 %), and WC above normal in 308 (70.2 %). Males were predominating in the nonobese compared to females in the obese (p = 0.001). Hypertriglyceridemia and low high-density lipoprotein was similar in the obese and nonobese (76.2 % vs. 72.3 %, p = 0.5 and 65.2 % vs. 64.6 %, p = 1.0, respectively). The grades of steatosis, lobular inflammation, ballooning, NAS, and the stage of fibrosis did not also significantly differ between obese and nonobese patients. Nonalcoholic steatohepatitis (NASH) was 53.1 % in nonobese.
CONCLUSION: Nonobese was 25.6 % among NAFLD patients of Bangladesh, and 53.1 % of nonobese NAFLD cases were NASH. Though they were nonobese by BMI grade, they were metabolically similar to obese. Males were predominant in the nonobese, whereas females in the obese. NASH and fibrosis were similar in the obese and nonobese.

Entities:  

Mesh:

Year:  2014        PMID: 25023045     DOI: 10.1007/s12664-014-0488-5

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  40 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

2.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

3.  Prevalence of non-alcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes.

Authors:  A K Agarwal; Vineet Jain; Sumeet Singla; B P Baruah; Vivek Arya; Rajbala Yadav; Vivek Pal Singh
Journal:  J Assoc Physicians India       Date:  2011-06

Review 4.  Nonalcoholic fatty liver disease.

Authors:  Leon A Adams; Keith D Lindor
Journal:  Ann Epidemiol       Date:  2007-08-28       Impact factor: 3.797

5.  Prevalence of and risk factors for hepatic steatosis in Northern Italy.

Authors:  S Bellentani; G Saccoccio; F Masutti; L S Crocè; G Brandi; F Sasso; G Cristanini; C Tiribelli
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

6.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

7.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

8.  Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome.

Authors:  Deepa Uchil; D Pipalia; M Chawla; R Patel; Sonali Maniar; Archana Juneja
Journal:  J Assoc Physicians India       Date:  2009-03

Review 9.  Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.

Authors:  Elisa Fabbrini; Shelby Sullivan; Samuel Klein
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

10.  Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals.

Authors:  Elena Succurro; Maria A Marini; Simona Frontoni; Marta L Hribal; Francesco Andreozzi; Renato Lauro; Francesco Perticone; Giorgio Sesti
Journal:  Obesity (Silver Spring)       Date:  2008-06-12       Impact factor: 5.002

View more
  18 in total

Review 1.  Hepatocellular carcinoma and non-alcoholic fatty liver disease.

Authors:  Pegah Golabi; Logan Rhea; Linda Henry; Zobair M Younossi
Journal:  Hepatol Int       Date:  2019-11-07       Impact factor: 6.047

2.  The metabolic profiles and body composition of lean metabolic associated fatty liver disease.

Authors:  Yu-Ming Cheng; Jia-Horng Kao; Chia-Chi Wang
Journal:  Hepatol Int       Date:  2021-02-04       Impact factor: 6.047

3.  Editorial: "Lean" NAFLD: Metabolic Obesity with Normal BMI… Is It in the Genes?

Authors:  Curtis K Argo; Zachary H Henry
Journal:  Am J Gastroenterol       Date:  2017-01       Impact factor: 10.864

4.  Clinical, anthropometric, biochemical and histological character of nonalcoholic fatty liver disease without Insulin Resistance.

Authors:  Shahinul Alam; Kamrul Anam; Saiful Islam; Golam Mustafa; Ayub Al Mamun; Nooruddin Ahmad
Journal:  J Clin Exp Hepatol       Date:  2018-06-20

5.  Regulation of Inflammation by IL-17A and IL-17F Modulates Non-Alcoholic Fatty Liver Disease Pathogenesis.

Authors:  Daniel A Giles; Maria E Moreno-Fernandez; Traci E Stankiewicz; Monica Cappelletti; Stacey S Huppert; Yoichiro Iwakura; Chen Dong; Shiva K Shanmukhappa; Senad Divanovic
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

6.  Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study.

Authors:  Hannes Hagström; Patrik Nasr; Mattias Ekstedt; Ulf Hammar; Per Stål; Rolf Hultcrantz; Stergios Kechagias
Journal:  Hepatol Commun       Date:  2017-11-30

Review 7.  Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications.

Authors:  Ramesh Kumar; Shantam Mohan
Journal:  J Clin Transl Hepatol       Date:  2017-07-05

8.  Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study.

Authors:  Omar T Ahmed; Tolga Gidener; Kristin C Mara; Joseph J Larson; Terry M Therneau; Alina M Allen
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-13       Impact factor: 13.576

9.  Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial.

Authors:  Shahinul Alam; Jahangir Kabir; Golam Mustafa; UtpalDas Gupta; S K M Nazmul Hasan; A K M Khorshed Alam
Journal:  Saudi J Gastroenterol       Date:  2016 Jan-Feb       Impact factor: 2.485

Review 10.  Fatty liver without a large "belly": Magnified review of non-alcoholic fatty liver disease in non-obese patients.

Authors:  Mohamad H Yousef; Alhareth Al Juboori; Abdulmajeed A Albarrak; Jamal A Ibdah; Veysel Tahan
Journal:  World J Gastrointest Pathophysiol       Date:  2017-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.